ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Aslan Pharma (ASLN) PT Lowered to $10 at Piper Sandler
March 13, 2024 6:41 AM EDTPiper Sandler analyst Edward A. Tenthoff lowered the price target on Aslan Pharma (NASDAQ: ASLN) to $10.00 (from $15.00) while maintaining a Overweight rating.
The analyst comments "Aslan ended 3Q:23 with cash of $40.8 million and debt of $38 million. The company issued 5 million and 5 million warrants... More
